• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Gilead Sciences

Gilead Sciences

Gilead Sciences Inc GILD 3 Star

Last Price$102.21Day Change (%)1.45%
Open Price$101.13Day Change ($)1.46
Day Range100.82–103.5952-Week Range63.50–110.64

As of Mon 10/20/2014 07:14 PM EST | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. UPDATE: Gilead's new drug is even pricier than Sovaldi

    UPDATE: Gilead's new drug is even pricier than Sovaldi

  2. UPDATE: Gilead's new drug is even pricier than Sovaldi

    UPDATE: Gilead's new drug is even pricier than Sovaldi

  3. UPDATE: Gilead's new drug is even pricier than Sovaldi

    UPDATE: Gilead's new drug is even pricier than Sovaldi

  4. European CHMP Adopts Positive Opinion for Gilead ’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults

    European CHMP Adopts Positive Opinion for Gilead ’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults

  5. NYSE to expand number of companies on biotech index

    NYSE to expand number of companies on biotech index

  6. Charting the October technical breakdown -- -2-

    Charting the October technical breakdown -- -2-

  7. Gilead Sciences Carving Out a Wider Moat

    StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.

  8. AHF Hammers Gilead on “Unsustainable” $94.5K Price of New Hepatitis C Drug, Harvoni

    AHF Hammers Gilead on “Unsustainable” $94.5K Price of New Hepatitis C Drug, Harvoni

  9. Research and Markets: Global Pancreatic Cancer Market 2014-2018: Key Vendors are Celgene, Eli Lilly, F. Hoffmann-La Roche, Novartis and Pfizer

    Research and Markets: Global Pancreatic Cancer Market 2014-2018: Key Vendors are Celgene, Eli Lilly, F. Hoffmann-La Roche, Novartis and Pfizer

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.